213 related articles for article (PubMed ID: 7966611)
21. Mouse adaptation determinants of poliovirus type 1 enhance viral uncoating.
Couderc T; Delpeyroux F; Le Blay H; Blondel B
J Virol; 1996 Jan; 70(1):305-12. PubMed ID: 8523541
[TBL] [Abstract][Full Text] [Related]
22. Cell clones cured of persistent poliovirus infection display selective permissivity to the wild-type poliovirus strain Mahoney and partial resistance to the attenuated Sabin 1 strain and Mahoney mutants.
Calvez V; Pelletier I; Couderc T; Pavio-Guédo N; Blondel B; Colbère-Garapin F
Virology; 1995 Oct; 212(2):309-22. PubMed ID: 7571400
[TBL] [Abstract][Full Text] [Related]
23. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
[TBL] [Abstract][Full Text] [Related]
24. Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice.
Couderc T; Guédo N; Calvez V; Pelletier I; Hogle J; Colbère-Garapin F; Blondel B
J Virol; 1994 Dec; 68(12):8386-91. PubMed ID: 7966631
[TBL] [Abstract][Full Text] [Related]
25. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
Heinz BA; Rueckert RR; Shepard DA; Dutko FJ; McKinlay MA; Fancher M; Rossmann MG; Badger J; Smith TJ
J Virol; 1989 Jun; 63(6):2476-85. PubMed ID: 2542566
[TBL] [Abstract][Full Text] [Related]
26. Acid-induced structural changes in human rhinovirus 14: possible role in uncoating.
Giranda VL; Heinz BA; Oliveira MA; Minor I; Kim KH; Kolatkar PR; Rossmann MG; Rueckert RR
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10213-7. PubMed ID: 1332036
[TBL] [Abstract][Full Text] [Related]
27. Isolation and biological characterization of 3(2H)-isoflavene-resistant and -dependent poliovirus type 2 Sabin mutants.
Genovese D; Catone S; Farah ME; Gambacorta A; Fiore L
J Gen Virol; 1999 Jan; 80 ( Pt 1)():157-167. PubMed ID: 9934698
[TBL] [Abstract][Full Text] [Related]
28. Two amino acid substitutions in the type 3 poliovirus capsid contribute to the establishment of persistent infection in HEp-2c cells by modifying virus-receptor interactions.
Duncan G; Pelletier I; Colbère-Garapin F
Virology; 1998 Feb; 241(1):14-29. PubMed ID: 9454713
[TBL] [Abstract][Full Text] [Related]
29. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans.
Porter DC; Ansardi DC; Morrow CD
J Virol; 1995 Mar; 69(3):1548-55. PubMed ID: 7853488
[TBL] [Abstract][Full Text] [Related]
30. One amino acid change on the capsid surface of poliovirus sabin 1 allows the establishment of persistent infections in HEp-2c cell cultures.
Pelletier I; Duncan G; Colbère-Garapin F
Virology; 1998 Feb; 241(1):1-13. PubMed ID: 9454712
[TBL] [Abstract][Full Text] [Related]
31. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor.
Colston E; Racaniello VR
EMBO J; 1994 Dec; 13(24):5855-62. PubMed ID: 7813425
[TBL] [Abstract][Full Text] [Related]
32. Conditional poliovirus mutants made by random deletion mutagenesis of infectious cDNA.
Kirkegaard K; Nelsen B
J Virol; 1990 Jan; 64(1):185-94. PubMed ID: 2152811
[TBL] [Abstract][Full Text] [Related]
33. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3.
Minor PD; Dunn G; Evans DM; Magrath DI; John A; Howlett J; Phillips A; Westrop G; Wareham K; Almond JW
J Gen Virol; 1989 May; 70 ( Pt 5)():1117-23. PubMed ID: 2543771
[TBL] [Abstract][Full Text] [Related]
34. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
Speelman B; Brooks BR; Post CB
Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
[TBL] [Abstract][Full Text] [Related]
35. Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus.
Pavio N; Couderc T; Girard S; Sgro JY; Blondel B; Colbère-Garapin F
Virology; 2000 Sep; 274(2):331-42. PubMed ID: 10964776
[TBL] [Abstract][Full Text] [Related]
36. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the poliovirus 147S particle: new insights into poliovirus uncoating.
Pelletier I; Ouzilou L; Arita M; Nomoto A; Colbère-Garapin F
Virology; 2003 Jan; 305(1):55-65. PubMed ID: 12504541
[TBL] [Abstract][Full Text] [Related]
38. Genome delivery and ion channel properties are altered in VP4 mutants of poliovirus.
Danthi P; Tosteson M; Li QH; Chow M
J Virol; 2003 May; 77(9):5266-74. PubMed ID: 12692228
[TBL] [Abstract][Full Text] [Related]
39. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.
Liu HM; Roberts JA; Moore D; Anderson B; Pallansch MA; Pevear DC; Collett MS; Oberste MS
Antimicrob Agents Chemother; 2012 Nov; 56(11):5568-74. PubMed ID: 22890765
[TBL] [Abstract][Full Text] [Related]
40. Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition.
Colston EM; Racaniello VR
J Virol; 1995 Aug; 69(8):4823-9. PubMed ID: 7609049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
